Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026)
Scilex Holding (SCLX) recorded quarterly Other Non Operating Income of -$279000.0 in Q1 2026, down 100.34% quarter-over-quarter from $82.1 million in Q4 2025, and down 102.68% on a YoY basis from $10.4 million in Q1 2025.
Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Scilex Holding's Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$279000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 102.68% year-over-year to -$279000.0; the TTM figure through Mar 2026 stood at $81.7 million (up 222.33% YoY), while the FY2025 annual figure was $21.8 million, up 25.45% from the prior year.
- Other Non Operating Income was -$279000.0 for Q1 2026 at Scilex Holding, down from $82.1 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $82.1 million in Q4 2025 to a low of -$5.3 million in Q1 2023.
- Historically, Other Non Operating Income has averaged $6.7 million across 5 years, with a median of -$2000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income plunged 4047.37% in 2022, then soared 13593.55% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at $3.0 million in 2022, then slumped by 67.71% to $972000.0 in 2023, then jumped by 1444.34% to $15.0 million in 2024, then surged by 447.09% to $82.1 million in 2025, then tumbled by 100.34% to -$279000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$279000.0 (Q1 2026), $82.1 million (Q4 2025), and -$2000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279,000.00 |
| Dec 31, 2025 | 82.12 Mn |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -99,000.00 |
| Mar 31, 2025 | 10.40 Mn |
| Dec 31, 2024 | 15.01 Mn |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -457,000.00 |
| Dec 31, 2023 | 972,000.00 |
| Sep 30, 2023 | 4.25 Mn |
| Jun 30, 2023 | -82,000.00 |
| Mar 31, 2023 | -5.25 Mn |
| Dec 31, 2022 | 3.01 Mn |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | -9.86 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 68,400.00 |